PROpranolol for Cerebral Hemorrhage-ASsociated pnEumonia (PRO-CHASE)
Status:
Not yet recruiting
Trial end date:
2025-07-03
Target enrollment:
Participant gender:
Summary
Stroke-associated pneumonia (SAP) is a grave complication of stroke and one of the most
important predictors for patients' poor outcomes. Stroke associated pneumonia and other
infections limit the overall efficacy of stroke management. Increasing evidence suggests that
sympathetic nervous system activity contributes to post stroke immunosuppression and
emergence of infections. This study is designed to test the safety and efficacy of an
adrenergic β receptor blocker propranolol in reducing SAP in hemorrhagic stroke patients, in
multi-center, randomized, placebo controlled, double blinded fashion.